NCT04708327View on ClinicalTrials.gov

Single-Blind Study of STAT-205 in Mild COVID-19

PHASE1UnknownINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 5, 2021

Primary Completion Date

June 30, 2022

Study Completion Date

September 30, 2022

Conditions
COVID-19
Interventions
DRUG

STAT-205

naltrexone hydrochloride capsules 4.5 mg each

Trial Locations (2)

33060

RECRUITING

Clinical Research Center of Florida, Pompano Beach

92354

RECRUITING

Loma Linda University, Loma Linda

Sponsors

Lead Sponsor

Cytocom, Inc.
All Listed Sponsors
lead

Cytocom, Inc.

INDUSTRY